Drug Shortage Report for MYTOLAC
| Report ID | 274972 |
| Drug Identification Number | 02555883 |
| Brand name | MYTOLAC |
| Common or Proper name | LANREOTIDE (LANREOTIDE ACETATE) |
| Company Name | ADVANZ PHARMA CANADA INC. |
| Market Status | MARKETED |
| Active Ingredient(s) | LANREOTIDE |
| Strength(s) | 120MG |
| Dosage form(s) | SOLUTION (EXTENDED RELEASE) |
| Route of administration | SUBCUTANEOUS |
| Packaging size | Box of one individual 120 mg MYTOLAC® dose in a 0.5 mL syringe + one stainless steel needle (18G X 20 mm) fitted with a shield |
| ATC code | H01CB |
| ATC description | HYPOTHALAMIC HORMONES |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2025-12-22 |
| Estimated end date | 2026-04-30 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-12-24 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 4263 SHERWOODTOWNE BLVD. MISSISSAUGA, ONTARIO CANADA L4Z 1Y5 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-12-24 | French | Compare |
| v1 | 2025-12-24 | English | Compare |
Showing 1 to 2 of 2